Clinical trial
Study of the Combination of Bortezomib, Dexamethasone, and Rituximab in Patients…
NCT00250926 · Dana-Farber Cancer Institute, Other · Completed
Key facts
| NCT number | NCT00250926 |
|---|---|
| Title | Study of the Combination of Bortezomib, Dexamethasone, and Rituximab in Patients With Waldenstroms Macroglobulinemia |
| Official title | A Phase II Study of the Combination Bortezomib (Velcade, PS-341), Dexamethasone, and Rituximab in Patients With Waldenstroms Macroglobulinemia |
| Lead sponsor | Dana-Farber Cancer Institute, Other |
| Collaborators | Beth Israel Deaconess Medical Center Millennium Pharmaceuticals, Inc. Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Waldenstrom's Macroglobulinemia |
| Intervention type | Drug |
| Interventions | Bortezomib, Dexamethasone, Rituximab |
| Enrollment | 23 |
| Start date | Oct 1, 2005 |
| Primary completion | Mar 1, 2007 |
| Completion | Feb 1, 2009 |
| First posted | Nov 9, 2005 |
| Last update posted | Apr 8, 2016 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: